The clinical potential of ARGX-111, an afucosylated anti-MET antibody, in hematological malignancies and suppression of metastasis

Hanssens, Valérie; Jonge, Natalie De; Hultberg, Anna; Borg, Christophe; Michieli, Paolo; Dreier, Torsten; Haard, Hans de; Thibault, Alain

doi:10.1093/annonc/mdv096.2

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ARGX111, a human monoclonal antibody not only blocks HGF/MET signaling but is also capable of killing circulating MET-expressing cancer cells through enhanced antibody-dependent cell-mediated cytotoxicity, [200]. This antibody is currently being tested in an ongoing phase I trial in patients with MET-positive hematological malignancies and solid tumors associated with circulating tumor cells (NCT02055066).…”

Section: Met/hgf Antibodiesmentioning

confidence: 99%

See 1 more Smart Citation

MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer

Pérez-Ramírez

Cañadas-Garre

Molina

et al. 2015

Pharmacological Research

View full text Add to dashboard Cite

Section: Met/hgf Antibodiesmentioning

confidence: 99%

“…MET Eli Lilly [196][197][198] ABT-700 MET AbbVie [199] ARGX111 MET arGEN-x [200] TAK-701 HGF Takeda Pharmaceutical Co [201] …”

Section: Antibodiesmentioning

confidence: 99%

MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer

Pérez-Ramírez

Cañadas-Garre

Molina

et al. 2015

Pharmacological Research

View full text Add to dashboard Cite

Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy

Kim

2017

Exp Mol Med

View full text Add to dashboard Cite

Dysregulated receptor tyrosine kinase signaling in human cancer cells leads to tumor progression, invasion and metastasis. The receptor tyrosine kinase cMET is frequently overexpressed in cancer tissue, and activation of cMET signaling is related to drug resistance and the processes of carcinogenesis, invasion and metastasis. For that reason, cMET and its ligand, hepatocyte growth factor (HGF), are considered prime targets for the development of anticancer drugs. At least eight anti-cMET and four anti-HGF antibodies have been tested or are being tested in clinical trials. However, to date none of these HGF/cMET inhibitors have shown significant efficacy in clinical trials. Furthermore, no receptor tyrosine kinase inhibitors primarily targeting cMET have been approved. Given that neutralization of HGF or cMET does not cause significant adverse effects, inhibition of the HGF/cMET signaling pathway appears to be safe. In this review, we summarized the completed and ongoing clinical trials testing antibody- or protein-based anticancer drugs targeting cMET and HGF.

show abstract

C-MET inhibitors for advanced non-small cell lung cancer

Pasquini

Giaccone

2018

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

The role of the c-mesenchymal-epithelial transition factor (c-MET) signaling pathway in tumor progression and invasion has been extensively studied. C-MET inhibitors have shown anti-tumor activity in NSCLC both in preclinical and in clinical trials. However, given the molecular heterogeneity of NSCLC, it is likely that only a specific subset of NSCLC patients will benefit from c-MET inhibitors. Emerging data also suggest that MET inhibitors in combination with EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors) may have a role in therapy for both EGFR-TKI resistant and EGFR-TKI naïve patients. The challenges ahead are in the identification of the molecular subtypes that benefit most. Areas covered: This review summarizes the current understanding of c-MET biology in relation to studies evaluating c-MET inhibitors in the treatment of NSCLC. Expert opinion: MET inhibitors have the potential to benefit subsets of NSCLC patients with specific genetic alterations. Exon-14 skipping mutations appear so far to be the most promising molecular subset that is sensitive to MET inhibitors, whereas overexpression, amplification and point mutations of MET seem more challenging subgroups to target. Combination with other target agents, such as EGFR inhibitors, may represent a promising therapeutic strategy in specific areas (e.g. EGFR-TKI resistance).

show abstract

The clinical potential of ARGX-111, an afucosylated anti-MET antibody, in hematological malignancies and suppression of metastasis

Cited by 3 publications

References 0 publications

MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer

MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer

Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy

C-MET inhibitors for advanced non-small cell lung cancer

Contact Info

Product

Resources

About